Latest Breaking News On - Aid nutromics 39 co founder and ceo peter vranes is developinga wearable diagnostic platform that uses dna technology to enable tracking for multiple targets in the human body usinga single patch this first of its kind botha proven work on sensor will provide clinicians patients with continuous real time information ranging from hard dose drugs - Page 1 : comparemela.com

MELBOURNE, Australia and SAN DIEGO, Sept. 8, 2022 /PRNewswire/ Global MedTech start-up Nutromics has raised an additional US $14 million for its wearable diagnostic platform. This transformative funding is key to Nutromics' continued expansion across Australia and the United States. Strategic investors included Dexcom Ventures, VU Venture Partners, and Artesian Investments. This funding demonstrates a resounding level of investor confidence in the potential of Nutromics' technology, which will tackle some of healthcare's most challenging conditions through the power of continuous diagnostic monitoring. Nutromics plans to raise significantly more funding in 2023 following in-vivo clinical studies. "We are aiming to cause a paradigm shift in diagnostic healthcare by essentially developing a lab-on-a-patch. A lack of timely and continuous diagnostic insights can strongly impact outcomes when dealing with critical disease states. With this strategic industry and VC inves

United statesPeter vranesDexcom venturesHitesh mehtaUstralia and san diegoSept 8022 prnewswire global medtech start up nutromics has raised an additional us 14 million for its wearable diagnostic platform this transformative funding is key to 39 continued expansion across australia and the united states strategic investors included dexcom venturesU venture partnersNd artesian investments this funding demonstratesa resounding level of investor confidence in the potential nutromics 39 technologyHich will tackle some of healthcare 39s most challenging conditions through the power continuous diagnostic monitoring nutromics plans to raise significantly more funding in 2023 following vivo clinical studies quot we are aiming causea paradigm shift by essentially developinga lab ona patcha lack timely and insights can strongly impact outcomes when dealing with critical disease states this strategic industry vc investment usE see more confidence in our technology and hope to accelerate growthS the need for our platform in lab diagnostic space is urgent quotAid nutromics 39 co founder and ceo peter vranes is developinga wearable diagnostic platform that uses dna technology to enable tracking for multiple targets in the human body usinga single patch this first of its kind botha proven work on sensor will provide clinicians patients with continuous real time information ranging from hard dose drugsIke vancomycinO biological markers for conditions such as kidney disease nutromics was founded in 2017 and including this recent acceleration round has raised over us 20 million to date its ground breaking wearable diagnostic platform latest of funding will support an expansion clinical studiesXpansion ofr ampd team and investment across both australian united states hubs the company 39s exponential growth over last year